A drug, usually applied topically, that relieves pruritus (itching).
| Member | Definition | Class |
|---|
| benzocaine | A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina. | benzocaine |
| chlorpheniramine | A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma. | chlorphenamine |
| clemastine | 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions. | clemastine |
| clemastine fumarate | The fumaric acid salt of clemastine. An antihistamine with antimuscarinic and moderate sedative properties, it is used for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions. | clemastine fumarate |
| clocortolone pivalate | The 21-O-pivalate ester of clocortolone. It is used for the relief of inflammatory and pruritic (itching) skin disorders. | clocortolone pivalate |
| crotamiton | An enamide resulting from the formal condensation of crotonic acid with N-ethyl-2-methylaniline. A colourless or pale yellow oily liquid, it is used in the treatment of pruritus (itching) by producing a counter-irritation: as it evaporates from the skin, it produces a cooling effect that diverts attention away from the itching. It has also been used as an acaricide in the treatment of scabies, though more effective drugs are usually preferred. | crotamiton |
| cyproheptadine | The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia. | cyproheptadine |
| desoximetasone | Dexamethasone in which the hydroxy group at the 17alpha position is substituted by hydrogen. A synthetic corticosteroid with glucocorticoid activity, it is used as an anti-inflammatory and anti-pruritic in the treatment of various skin disorders, including skin allergies and psoriasis. | desoximetasone |
| diflorasone diacetate | The 17,21-diacetate derivative of diflorasone. It is used topically for its anti-inflammatory and antipruritic properties in the treatment of various skin disorders. | diflorasone diacetate |
| diphenhydramine | An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug. | diphenhydramine |
| diphenhydramine hydrochloride | The hydrochloride salt of diphenhydramine. | diphenhydramine hydrochloride |
| emedastine | 1-Methyl-1,4-diazepane in which the hydrogen attached to the nitrogen at position 4 is substituted by a 1-(2-ethoxyethyl)-1H-benzimidazol-2-yl group. A relatively selective histamine H1 antagonist, it is used as the difumatate salt for allergic rhinitis, urticaria, and pruritic skin disorders, and in eyedrops for the symptomatic relief of allergic conjuntivitis. | emedastine |
| ethyl chloride | The simplest and least toxic member of the class of chloroethanes, that is ethane in which a single hydrogen is substituted by a chlorine. A colourless gas at room temperature and pressure (boiling point 12degreeC), it is used as a mild topical anaesthetic to numb the skin prior to ear piercing, skin biopsies, etc., and is also used in the treatment of sports injuries. It was formerly used in the production of tetraethyllead. | chloroethane |
| flumethasone pivalate | | flumethasone pivalate |
| fluocinolone acetonide | A fluorinated steroid that is flunisolide in which the hydrogen at position 9 is replaced by fluorine. A corticosteroid with glucocorticoid activity, it is used (both as the anhydrous form and as the dihydrate) in creams, gels and ointments for the treatment of various skin disorders. | fluocinolone acetonide |
| hydroxyzine | A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively. | hydroxyzine |
| menthol | A p-menthan-3-ol which has (1R,2S,5R)-stereochemistry. It is the most common naturally occurring enantiomer. | (-)-menthol |
| methdilazine | A phenothiazine substituted on nitrogen by a (1-methylpyrrolidin-3-yl)methyl group; a first-generation antihistamine with anticholinergic properties. | methdilazine |
| promethazine | A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety. | promethazine |
| promethazine hydrochloride | The hydrochloride salt of promethazine. | promethazine hydrochloride |
| quercetin 3-o-glucopyranoside | A quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 3. Isolated from Lepisorus contortus, it exhibits antineoplastic activityand has been found to decrease the rate of polymerization and sickling of red blood cells | quercetin 3-O-beta-D-glucopyranoside |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| acetylcholinesterase | Homo sapiens (human) | Potency | 36.0666 | 3 | 6 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 54.9410 | 1 | 1 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 38.7306 | 1 | 2 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 3.5481 | 1 | 1 |
| AR protein | Homo sapiens (human) | Potency | 19.7005 | 10 | 67 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 35.6787 | 2 | 7 |
| arylsulfatase A | Homo sapiens (human) | Potency | 0.0120 | 1 | 1 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 13.1386 | 3 | 4 |
| Ataxin-2 | Homo sapiens (human) | Potency | 29.6719 | 2 | 7 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 23.0515 | 2 | 3 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 42.3018 | 2 | 4 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 8.4921 | 1 | 1 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 17.4745 | 1 | 2 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 0.0063 | 2 | 2 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 44.6684 | 1 | 1 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 57.1928 | 1 | 3 |
| caspase-3 | Homo sapiens (human) | Potency | 57.1928 | 1 | 3 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 31.9646 | 2 | 12 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 13.4042 | 2 | 4 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 19.1373 | 1 | 3 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 25.1189 | 1 | 1 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 19.9526 | 1 | 1 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 79.4328 | 1 | 1 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 10.7589 | 1 | 4 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| chaperonin GroEL | Methanococcus maripaludis S2 | Potency | 100.0000 | 1 | 1 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 56.7519 | 2 | 4 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 11.4674 | 1 | 5 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 19.6370 | 1 | 5 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 1.9866 | 1 | 5 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 7.3639 | 1 | 8 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 13.7606 | 2 | 11 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 11.2690 | 2 | 8 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 18.6262 | 1 | 9 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 3.9176 | 2 | 4 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 14.6892 | 1 | 1 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 1.7783 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 65.8114 | 1 | 2 |
| endonuclease IV | Escherichia coli | Potency | 50.1187 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 27.8392 | 10 | 57 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 39.7308 | 2 | 7 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 38.8102 | 7 | 45 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 19.0024 | 2 | 10 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 24.4222 | 4 | 10 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 22.3872 | 1 | 1 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 34.4226 | 1 | 2 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 8.4368 | 1 | 2 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 20.7999 | 1 | 3 |
| G | Vesicular stomatitis virus | Potency | 19.6370 | 1 | 5 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 13.4472 | 1 | 6 |
| geminin | Homo sapiens (human) | Potency | 9.4954 | 3 | 8 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 23.7184 | 2 | 23 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 7.3133 | 2 | 2 |
| GLS protein | Homo sapiens (human) | Potency | 21.1770 | 2 | 3 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 17.7828 | 1 | 1 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 13.0212 | 3 | 26 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 26.0281 | 1 | 6 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 1.1582 | 1 | 1 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 19.3568 | 2 | 17 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 71.2490 | 2 | 5 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 70.7946 | 1 | 1 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 19.6370 | 1 | 5 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 33.0488 | 1 | 3 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 12.9070 | 1 | 2 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 2.5213 | 2 | 10 |
| IDH1 | Homo sapiens (human) | Potency | 1.2279 | 1 | 2 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 1.1582 | 1 | 1 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 19.6370 | 1 | 10 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 1.0650 | 1 | 3 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| Interferon beta | Homo sapiens (human) | Potency | 15.8243 | 3 | 9 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 12.7965 | 1 | 8 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 9.2758 | 1 | 4 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 27.4852 | 2 | 3 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 3.5481 | 1 | 1 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 33.2451 | 1 | 2 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 11.4642 | 1 | 2 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 11.4543 | 2 | 5 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 0.5172 | 2 | 6 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 1.9953 | 1 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 34.5267 | 3 | 9 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 0.0201 | 2 | 5 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 11.0388 | 1 | 2 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 14.7334 | 1 | 2 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 4.9282 | 1 | 4 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 45.2603 | 3 | 14 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 20.0260 | 1 | 4 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 84.9214 | 1 | 2 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 23.1299 | 4 | 7 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 38.3898 | 5 | 12 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 66.8484 | 2 | 4 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 2.2387 | 1 | 1 |
| polyprotein | Zika virus | Potency | 20.7999 | 1 | 3 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 16.7284 | 1 | 7 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 12.3332 | 1 | 6 |
| PPM1D protein | Homo sapiens (human) | Potency | 14.7403 | 1 | 2 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 24.1339 | 3 | 12 |
| progesterone receptor | Homo sapiens (human) | Potency | 10.8834 | 3 | 11 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 23.8944 | 2 | 13 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 7.8386 | 1 | 4 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 37.3393 | 3 | 25 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 29.8824 | 3 | 11 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 18.5000 | 2 | 3 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 29.9680 | 2 | 4 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 29.9680 | 2 | 4 |
| Smad3 | Homo sapiens (human) | Potency | 0.1000 | 1 | 1 |
| snurportin-1 | Homo sapiens (human) | Potency | 1.1582 | 1 | 1 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 26.4639 | 2 | 7 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 1.7047 | 1 | 4 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 17.3204 | 1 | 3 |
| TDP1 protein | Homo sapiens (human) | Potency | 25.0994 | 2 | 22 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 11.2202 | 1 | 1 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 38.9671 | 3 | 6 |
| Thrombopoietin | Homo sapiens (human) | Potency | 5.0316 | 2 | 4 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 33.7293 | 3 | 23 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 3.5481 | 1 | 1 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 23.7837 | 6 | 13 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 17.3768 | 1 | 1 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 15.8489 | 1 | 1 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 2.2387 | 1 | 1 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 2.2387 | 1 | 1 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 39.8107 | 1 | 2 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 16.8506 | 2 | 17 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 42.7674 | 3 | 8 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 94.5626 | 1 | 2 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 26.0281 | 1 | 6 |